高雄醫學大學圖書館 |

GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging // Emily Ngu.
Author:	Ngu, Emily,
Description:	1 electronic resource (58 pages)
Notes:	Source: Masters Abstracts International, Volume: 86-07.
基督教聖經之智慧書導讀 :	Outside of its role in the central nervous system as an inhibitory neurotransmitter, ɣ-aminobutyric-acid (GABA) acts as a hepatokine within the liver. NAFLD is associated with increased risk of developing HCC. We have previously demonstrated obesity increases production and excretion of hepatic GABA. Furthermore, GABA can drive the progression of HCC. In regards to aging, obesity shortens lifespan and healthspan, thus contributing to accelerated aging. We performed two studies assessing the effects of GABA-transaminase inhibition on NAFLD-associated HCC and age-associated metabolic and physical declines. To assess the role of GABA within NAFLD-associated HCC, we created an accelerated diet-sensitive mouse model and targeted hepatic GABA production using ethanolamine-O-sulfate (EOS), a GABA-transaminase inhibitor. We found HCC decreased mRNA expression of the GABA shunt enzymes (GABA-transaminase and succinate semialdehyde dehydrogenase), decreased mRNA expression of export-type GABA transporters (SLC6A12 and SCL6A13), and decreased mRNA expression of GABA A receptor subunits. Overall, GABA-transaminase inhibition using EOS had no effect on tumor burden after 16 weeks of exposure to cancer-causing stimuli. To assess the role of GABA in aging, we tested measures of metabolic and physical performance in 6 months-old-, 12 months-old-, and 18 months-old-mice. After administering EOS for 4 weeks, we observed modest improvements to glucose clearance, basal insulin, and all-limb grip strength in aged mice. Additionally, GABA-transaminase inhibition caused weight loss and lowered serum triglycerides in both young and aged mice.
Contained By:	Masters Abstracts International86-07.
Subject:	Aging. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31763566
ISBN:	9798302159663

GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging /
Ngu, Emily,

GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging /Emily Ngu. - 1 electronic resource (58 pages)

Source: Masters Abstracts International, Volume: 86-07.

Outside of its role in the central nervous system as an inhibitory neurotransmitter, ɣ-aminobutyric-acid (GABA) acts as a hepatokine within the liver. NAFLD is associated with increased risk of developing HCC. We have previously demonstrated obesity increases production and excretion of hepatic GABA. Furthermore, GABA can drive the progression of HCC. In regards to aging, obesity shortens lifespan and healthspan, thus contributing to accelerated aging. We performed two studies assessing the effects of GABA-transaminase inhibition on NAFLD-associated HCC and age-associated metabolic and physical declines. To assess the role of GABA within NAFLD-associated HCC, we created an accelerated diet-sensitive mouse model and targeted hepatic GABA production using ethanolamine-O-sulfate (EOS), a GABA-transaminase inhibitor. We found HCC decreased mRNA expression of the GABA shunt enzymes (GABA-transaminase and succinate semialdehyde dehydrogenase), decreased mRNA expression of export-type GABA transporters (SLC6A12 and SCL6A13), and decreased mRNA expression of GABA A receptor subunits. Overall, GABA-transaminase inhibition using EOS had no effect on tumor burden after 16 weeks of exposure to cancer-causing stimuli. To assess the role of GABA in aging, we tested measures of metabolic and physical performance in 6 months-old-, 12 months-old-, and 18 months-old-mice. After administering EOS for 4 weeks, we observed modest improvements to glucose clearance, basal insulin, and all-limb grip strength in aged mice. Additionally, GABA-transaminase inhibition caused weight loss and lowered serum triglycerides in both young and aged mice.

English

ISBN: 9798302159663Subjects--Topical Terms:

215852
Aging.
Subjects--Index Terms:

Hepatocellular carcinoma

GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging /
LDR:03132nam a22004453i 4500 001 391470
005 20251124054802.5
006 m o d
007 cr|nu||||||||
008 251208s2024 miu||||||m |||||||eng d
020 $a 9798302159663
035 $a (MiAaPQD)AAI31763566
035 $a AAI31763566
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Ngu, Emily, $e author. $3 523999
245 1 0 $a GABA-T Inhibition and Its Effects on the Progression of Hepatocellular Carcinoma and Aging / $c Emily Ngu.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (58 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 86-07.
500 $a Advisors: Stern, Jennifer; Renquist, Benjamin Committee members: Yao, Guang.
502 $b M.S. $c The University of Arizona $d 2024.
520 $a Outside of its role in the central nervous system as an inhibitory neurotransmitter, ɣ-aminobutyric-acid (GABA) acts as a hepatokine within the liver. NAFLD is associated with increased risk of developing HCC. We have previously demonstrated obesity increases production and excretion of hepatic GABA. Furthermore, GABA can drive the progression of HCC. In regards to aging, obesity shortens lifespan and healthspan, thus contributing to accelerated aging. We performed two studies assessing the effects of GABA-transaminase inhibition on NAFLD-associated HCC and age-associated metabolic and physical declines. To assess the role of GABA within NAFLD-associated HCC, we created an accelerated diet-sensitive mouse model and targeted hepatic GABA production using ethanolamine-O-sulfate (EOS), a GABA-transaminase inhibitor. We found HCC decreased mRNA expression of the GABA shunt enzymes (GABA-transaminase and succinate semialdehyde dehydrogenase), decreased mRNA expression of export-type GABA transporters (SLC6A12 and SCL6A13), and decreased mRNA expression of GABA A receptor subunits. Overall, GABA-transaminase inhibition using EOS had no effect on tumor burden after 16 weeks of exposure to cancer-causing stimuli. To assess the role of GABA in aging, we tested measures of metabolic and physical performance in 6 months-old-, 12 months-old-, and 18 months-old-mice. After administering EOS for 4 weeks, we observed modest improvements to glucose clearance, basal insulin, and all-limb grip strength in aged mice. Additionally, GABA-transaminase inhibition caused weight loss and lowered serum triglycerides in both young and aged mice.
546 $a English
590 $a School code: 0009
650 4 $2 96060 $a Aging. $3 215852
650 4 $a Cellular biology. $3 523871
650 4 $2 96060 $a Biology. $3 202247
653 $a Hepatocellular carcinoma
653 $a Liver
653 $a Neurotransmitter
653 $a Obesity
653 $a Basal insulin
690 $a 0306
690 $a 0379
690 $a 0493
710 2 $a The University of Arizona. $b Molecular & Cellular Biology. $e degree granting institution. $3 524000
720 1 $a Stern, Jennifer $e degree supervisor.
720 1 $a Renquist, Benjamin $e degree supervisor.
773 0 $t Masters Abstracts International $g 86-07.
790 $a 0009
791 $a M.S.
792 $a 2024
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31763566